Novo’s Wegovy Pill Isn’t Just Beating Expectations — It’s Obliterating Them. Is the Beaten-Down Stock a Buy Now?
The pharmaceutical industry is highly competitive and driven by innovation. Those two facts couldn’t be on any clearer…
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
The global geopolitical landscape has plunged into a deep state of uncertainty once again following a direct exchange…
Can Wegovy Pill’s Rapid Uptake Give Novo Nordisk an Edge Over LLY?
Novo Nordisk NVO remains one of the dominant players in the rapidly expanding obesity treatment market. The company markets…
Forget Zepbound: Eli Lilly’s Next Billion-Dollar Weight-Loss Drug May Be Even Better
Eli Lilly (NYSE: LLY) has been posting incredible sales and earnings growth in recent quarters, thanks in no…
Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry
Quick Read NVIDIA and Eli Lilly’s $1 billion AI drug discovery partnership makes both stocks the primary public…
Weight Loss Drugs Listed By Health Insurers Aren’t Necessarily Covered
Eli Lilly’s Foundayo weight loss oral pill competes against Novo Nordisk’s oral Wegovy. (Photo by: Michael Siluk/UCG/Universal Images…
An experimental GLP-1 pushes the limits of weight loss. There are risks.
Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity…
Eli Lilly’s $1 trillion valuation cements its status as Wall Street’s ultimate weight-loss play
Eli Lilly (LLY) is back above $1 trillion, closing at its first record high since November, as Wall…
Lilly and Novo Weight-Loss Drugs Show Potential Cancer Benefits
This article first appeared on GuruFocus. Eli Lilly (LLY, Financials) and Novo Nordisk (NVO, Financials) may have another…
From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Eli Lilly saw…
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
By Bhanvi Satija and Chris Prentice LONDON/NEW YORK, May 21 (Reuters) – Lower prices for weight-loss pills from…
Weight lost with GLP-1 drugs still subject to rebound after stopping treatment – Baltimore Sun
Weight lost with GLP-1 drugs still subject to rebound after stopping treatment Baltimore SunA pill helps you keep weight…